Invex Therapeutics Valuation
| IXC Stock | 0.07 0.01 7.46% |
Invex Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Invex Therapeutics from evaluating the firm fundamentals such as Current Valuation of (613.99 K), return on equity of -0.12, and Return On Asset of -0.0922 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Invex Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Invex Therapeutics is based on 3 months time horizon. Increasing Invex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Invex Therapeutics' intrinsic value may or may not be the same as its current market price of 0.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.072 | Real 0.0628 | Hype 0.07 | Naive 0.078 |
The intrinsic value of Invex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Invex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Invex Therapeutics helps investors to forecast how Invex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Invex Therapeutics more accurately as focusing exclusively on Invex Therapeutics' fundamentals will not take into account other important factors: Invex Therapeutics Total Value Analysis
Invex Therapeutics is currently forecasted to have takeover price of (613.99 K) with market capitalization of 5.41 M, debt of 431.63 K, and cash on hands of . The negative valuation of Invex Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Invex Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(613.99 K) | 5.41 M | 431.63 K |
Invex Therapeutics Investor Information
About 68.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Invex Therapeutics recorded a loss per share of 0.02. The entity last dividend was issued on the 8th of December 2023. Based on the key indicators related to Invex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Invex Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Invex Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Invex Therapeutics has an asset utilization ratio of 19.81 percent. This implies that the Company is making USD0.2 for each dollar of assets. An increasing asset utilization means that Invex Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Invex Therapeutics Ownership Allocation
Invex Therapeutics has a total of 75.15 Million outstanding shares. Invex Therapeutics retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.72 (percent) of Invex Therapeutics outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Invex Therapeutics Profitability Analysis
The company reported the revenue of 1.21 M. Net Loss for the year was (1.64 M) with profit before overhead, payroll, taxes, and interest of 459.08 K.About Invex Therapeutics Valuation
The stock valuation mechanism determines Invex Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Invex Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Invex Therapeutics. We calculate exposure to Invex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Invex Therapeutics's related companies.Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.